Abstract
A growing body of evidence suggests that oxidative stress-mediated cell death signaling mechanisms may exert neurotoxic effects of methamphetamine (MA)-induced dopaminergic neuronal loss. However, the means by which oxidative stress induced by MA causes neurodegeneration remains unclear. In recent years, resveratrol has garnered considerable attention owing to its antioxidant, anti-inflammatory, anti-aging, and neuroprotective properties. In the present study, we sought to investigate the neuroprotective effects of resveratrol against apoptotic cell death in a mesencephalic dopaminergic neuronal cell culture model of MA neurotoxicity. MA treatment in the N27 dopaminergic neuronal cell model produced a time-dependent activation of the apoptotic cascade involving caspase-3 and DNA fragmentation. We found that the caspase-3 activation preceded DNA fragmentation. Notably, treatment with resveratrol almost completely attenuated MA-induced caspase-3 activity, but only partially reduced apoptotic cell death. We conclude that the neuroprotective effect of resveratrol is at least in part mediated by suppression of caspase-3 dependent cell death pathways. Collectively, our results demonstrate that resveratrol can attenuate MA-induced apoptotic cell death and suggest that resveratrol or its analogs may have therapeutic benefits in mitigating MA-induced dopaminergic neurodegeneration.
Keywords: Resveratrol, drug abuse, neuroprotection, neurotoxicity, oxidative stress, apoptosis.
INTRODUCTION
Methamphetamine (MA) is a psychostimulant that is widely abused in the US and worldwide [1]. Repeated use has been shown to be associated with euphoria, decreased appetite, increased alertness, and hyperthermia [2]. Several of these effects are believed to play a central role in the high abuse potential of MA, which causes not only severe health problems but also poor socioeconomic conditions for the abusers. MA use leads to functional alterations and neurodegenerative changes in various brain regions [3, 4]. Notably, decreased levels of tyrosine hydroxylase (TH) and dopamine transporter (DAT) immunoreactivity were measured in the striatum of MA users [5, 6]. Additionally, several studies have repeatedly demonstrated that in rodents MA causes long term neurodegenerative changes in dopaminergic and serotonergic nerve terminals in several brain regions, including the cortex, striatum, and hippocampus [7-9]. The changes include long term reductions in striatal dopamine (DA) and serotonin (5-HT) levels, decreased tryptophan hydroxylase and tyrosine hydroxylase, loss of DA and 5-HT transporters, and associated neurodegenerative changes in the monoaminergic terminals [10]. The loss of DA transporters has been documented in abstinent MA users; this deficiency is believed to contribute to reduced motor function and memory impairments [11]. Furthermore, based on the similaritiesbetween MA-induced dopaminergic neurodegenerative changes and PD-induced neuronal damage, MA has been used as a putative model for the study of dopaminergic terminal degeneration associated with Parkinsonism [12].
Although several mechanisms have been proposed to underlie MA-induced neurotoxicity, the exact mechanism remains unknown. Mounting evidence suggests that elevated oxidative stress may contribute to MA-induced degenerative changes. In fact, oxidative damage to proteins, lipids and DNA has been shown in the brains of MA-treated animals [13-15]. Accumulation of oxidative products may lead to activation of the apoptosis related cell death cascade. Increasing lines of evidence suggest that mitochondria-dependent apoptotic signaling events may underlie neurodegenerative changes associated with MA-induced neurotoxicity [16, 17]. Experimental evidence indicates that key events of MA-induced mitochondrial changes include membrane depolarization, Bcl2/Bax dysregulation, cytochrome C release, and capase-9 and -3 activation [18, 19]. Moreover, administration of antioxidants effectively attenuated key MA-induced mitochondrial dependent apoptotic changes, suggesting that oxidative stress plays a role in the neurotoxicity [20-22].
Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenolic phytoalexin found in the skin of red grapes, red wine, and other natural food sources such as nuts. Interestingly, resveratrol has been shown to possess a wide variety of biological and pharmacological effects, including antioxidant, anti-apoptotic, anti-inflammatory, anti-carcinogenic, and anti-aging properties [23-27] Furthermore, resveratrol has been shown to attenuate neuronal death associated with MPP+-induced oxidative stress [28-31]. However, currently there is no information available regarding the neuroprotective effects of resveratrol on MA-induced dopaminergic neurodegenerative effects. Hence, we hypothesized that resveratrol may also protect dopaminergic neurons against MA-induced neurotoxicity by modulating the caspase-3 dependent apoptotic cell death pathway. Therefore, we evaluated possible neuroprotective properties of resveratrol in a well characterized cell culture model of MA -induced dopaminergic neurotoxicity.
MATERIALS AND METHODS
Materials
Methamphetamine was obtained from the National Institute of Drug Abuse (NIDA) drug supply program. Caspase-3 substrate, Ac-DEVD-AFC, was purchased from EMD Biosciences, Inc. (Gibbs town, NJ). Cell Death Detection Elisa Plus Assay Kit was purchased from Roche Molecular Biochemicals (Indianapolis, IN). All tissue culture supplies were purchased from Gibco-BRL (Gaithersburg, MD). Other routine laboratory reagents were purchased from Fisher Scientific (Pittsburg, PA). The immortalized rat mesencephalic (N27) cell line was a kind gift of Dr. Kedar N. Prasad, Univ. of Colorado Health Sciences Center (Denver, CO).
Cell Culture Model
Immortalized rat mesencephalic neuronal cells (1RB3AN27, commonly referred to as N27 dopaminergic cells) were grown in RPMI medium supplemented with 10% fetal bovine serum, 1% L-glutamine, penicillin (100 U/ml), and streptomycin (100 U/ml), and maintained at 37°C in a humidified atmosphere of 5% CO2 (Anantharam, 2002; Clarkson, 1999). We previously reported that N27 neuronal cells can be used as a model system to study the apoptotic changes associated with neurotoxicity of dopaminergic neurotoxicants such as methamphetamine and MPP+ [32-34]. After 2-4 days in culture, N27 cells were harvested and resuspended in complete growth medium at a cell density of 1-3 x 106/ml. Cells were treated with 2 mM MA in the presence or absence of 10 µM resveratrol for 12 or 24 hr. Following the treatments, cells were homogenized and the lysates were used for caspase-3 and DNA fragmentation assays.
Measurement of Caspase-3 Activity
Caspase-3 activity was used as an early marker of apoptosis and was determined as previously described in our publications [35]. Briefly, cell lysates were then incubated at 37°C for 20-30 min to allow complete lysis. Lysates were quickly centrifuged and cell-free supernatants were incubated with 50 µM Ac-DEVD-AFC (caspase-3 substrate) at 37°C for 1 hr. Caspase activity was then measured by determining the formation of 7-amido-4-trifluoromethylcoumarin (AFC) resulting from caspase cleavage using a Biotek plate reader (excitation 400 nm, emission 505 nm). The fluorescence signals from the samples were normalized to protein concentration, which was measured by the Bradford protein assay.
DNA Fragmentation Analysis
DNA fragmentation assay was performed using a Cell Death Detection Elisa Plus Assay Kit, as described in our publications [35, 36]. Briefly, 20 µl aliquots of supernatant obtained from cell lysates were dispensed to streptavidin-coated 96 well microtiter plates followed by addition of 80 µl of antibody cocktail. Plates were incubated for 2 hr at RT with mild shaking. The antibody cocktail consisted of a mixture of anti-histone biotin and anti-DNA-HRP directed against various histones and antibodies to both single strand DNA and double strand DNA, which are major constituents of the nucleosomes. After incubation, unbound components were removed by washing with the incubation buffer supplied with the kit. Quantitative determination of the amount of nucleosomes retained by anti-DNA-HRP in the immunocomplex was conducted spectrophotometrically with ABTS as an HRP substrate (supplied with the kit). Measurements were made at 405 nm against an ABTS solution as a blank (reference wavelength ~490 nm) using a Biotek microplate reader.
RESULTS
Effects of Resveratrol on Methamphetamine-Induced Caspase-3 Activation
We previously demonstrated that caspase-3 activation is one of the key events in dopaminergic neurotoxicity caused by several neurotoxicants, including MA and MPP+ [32-34]. We also showed that caspase-3 activity can be used as a reliable marker for evaluation of neuroprotective efficacy of experimental pharmacological agents against diverse neurotoxicants [34-36]. Therefore, we first examined whether resveratrol attenuates MA-induced caspase-3 activation. As depicted in Fig. (1), treatment of N27 cells with 2 mM MA resulted in a significant increase (~130% increase; p<0.01) in caspase-3 activation as compared to the control group. However, cells that were pretreated with resveratrol for 1 hr prior to MA treatment showed significantly reduced caspase-3 activation as compared to MA treated cells. The resveratrol alone treated group did not show any significant changes in caspase-3 activation as compared to the control. These results indicate that resveratrol can attenuate activation of key proapoptotic changes following MA treatment.
Fig. (1). Resveratrol protects against methamphetamine-induced caspase-3 activity in a dopaminergic neuronal cell model.

N27 dopaminergic neuronal cells were pretreated with 10 µM resveratrol for 1 hr and then exposed to 2 mM methamphetamine (MA) for 12 hr. Caspase-3 activity was measured using the caspase-3 specific substrate Ac-DEVD-AFC, as described in “Materials and Methods.” Each bar represents mean ± SEM from four individual measurements. *p<0.01, comparison of control vs. MA treatment. **p<0.01, comparison of MA vs. MA and resveratrol treatment.
Effects of Resveratrol on Methamphetamine -Induced DNA Fragmentation
In order to determine whether resveratrol protects against MA-induced neuronal apoptosis, we measured DNA fragmentation in resveratrol treated cells. As shown in Fig. (2), MA significantly increased DNA fragmentation following a 24 hr treatment. The magnitude of increase in DNA fragmentation was about 2-fold in MA-treated cells as compared to the control group. We observed a significant reduction in DNA fragmentation in N27 cells pretreated with 10 uM resveratrol for 1 hr prior to MA treatment. In contrast, the resveratrol alone treated group did not have altered basal levels of DNA fragmentation. Collectively, these results demonstrate that resveratrol protects against MA-induced apoptosis in dopaminergic neuronal cells.
Fig. (2). Resveratrol attenuates methamphetamine-induced DNA fragmentation in a dopaminergic neuronal cell model.

N27 dopaminergic neuronal cells were pretreated with 10 µM resveratrol for 1 hr and then exposed to 2 mM methamphetamine (MA) for 24 hr. DNA fragmentation was measured using the ELISA based cell death assay kit, as described in “Materials and Methods.” Each bar represents mean ± SEM from four individual measurements. *p<0.01, comparison of control vs. MA treatment. **p<0.01, comparison of MA vs. MA and resveratrol treatment.
DISCUSSION
In the present study we examined the neuroprotective effects of a polyphenolic natural product, resveratrol, on MA-induced neurotoxicity. We show that pretreatment of mesencephalic dopaminergic cells with resveratrol conferred neuroprotection against MA-induced cell death. Specifically, resveratrol showed anti-apoptotic effects by blocking both caspase-3 activation and DNA fragmentation. Resveratrol treatment alone did not alter basal caspase-3 or DNA fragmentation, suggesting that low micromolar concentrations of the compound are not toxic to dopaminergic neuronal cells. To our knowledge, this is the first study demonstrating the neuroprotective efficacy of resveratrol against MA-induced neurotoxicity.
It is well known that MA causes long term neurodegenerative changes in dopaminergic and serotonergic nerve terminals in several brain regions including cortex, striatum, and hippocampus [37-39]. Neurotoxic mechanisms implicated in MA-induced neurodegneration include, mitochondrial dysfunction, oxidative stress, ER stress, and apoptosis. In fact, the critical contribution of oxidative stress related mechanisms in MA-induced dopaminergic neuronal degeneration has been described extensively, whereby accumulation of oxidatively damaged lipids [40], proteins [14], and DNA [15] has been shown in various brain regions of rodents as well as induction of oxidative stress mechanisms in in vitro dopaminergic cell culture models [10]. In addition, MA-induced displacement of DA from vesicles and subsequent buildup within the cytosolic and extracellular space and the resulting formation DA related oxidative product, quinone has been shown to be a critically involved in MA-induced dopaminergic neurotoxicity [41, 42]. Moreover, inhibitors of dopamine synthesis or release can attenuate cellular toxicity in experimental models [43]. Previous studies have suggested that oxidative stress may be an early event in dopaminergic neurodegeneration since neurotoxicity is attenuated by antioxidants such as trolox [44, 45] and glutathione (GSH) [43]. In a recent report, resveratrol inhibited ROS accumulation, depletion of GSH, and cellular oxidative damage following treatment with MPP+ as well as 6-OHDA, suggesting antioxidant factors are important neuroprotective effects of resveratrol [46-48]. Therefore, the contribution of antioxidant properties of resveratrol in preventing MA-induced cell death cannot be discounted.
MA-induced oxidative stress is functionally linked to mitochondrial dependent apoptosis, which has been proposed to play a central role in mediating neurotoxicity [18, 38]. MA is a cationic lipophilic molecule that diffuses into mitochondria and is retained there, resulting in dissipation of the mitochondrial membrane potential and disturbance of mitochondrial biogenesis [17]. Additionally, MA causes increases in pro-apoptotic proteins, namely Bax, Bad, and Bid, and decreases in anti-apoptotic proteins, Bcl-2 and Bcl-XL [18, 19]. Subsequently, release of mitochondrial cytochrome C, followed by activation of caspase-9 and -3, and breakdown of several proteins, including PARP, lamin, and DNA fragmentation factor 45 fragment (DFF-45) [18, 38] have been shown to participate in MA-induced apoptotic cell death. In this context, over-expression of Bcl-2 and inhibition of caspases confers resistance against MA-induced apoptotic cell death [10]. In the mitochondrial dependent apoptotic cascade, caspase-3 activation plays a central role in mediating DNA fragmentation, which ultimately leads to cell death [10, 18, 32, 38]. These studies underscore the importance of the mitochondrial mediated caspase cascade in MA-induced neurotoxicity. In the present study, resveratrol pretreatment almost completely inhibited MA-induced caspase-3 activation, but only partially inhibited MA-induced DNA fragmentation. These results suggest that MA-induced neurotoxicity is not entirely dependent on caspase-3 activation, and that other factors might play a role in the neurotoxicity. ER stress, ubiquitin dysfunction, and autophagic impairment may contribute to cell death. We recently reported that MA dramatically increases autophagy in a dopaminergic cell model [32], but the role of autophagy in MA-induced dopaminergic neuronal loss is currently being studied in our laboratory.
Recent studies have demonstrated that polyphenolic compounds exert protective effects against DA associated oxidative damage in dopaminergic neurons both in in vivo and in vitro models of dopaminergic neuronal degeneration [48-50]. Resveratrol has multiple pharmacological properties: antioxidant, anti-inflammatory, cardioprotective and anti-aging properties [51]. Emerging studies indicate that resveratrol extends the lifespan via the sirtuin pathway [52]. Resveratrol’s antioxidant properties might be partly mediated by increases in SOD and catalase activity [52]. Nevertheless, the antioxidant property alone cannot account for its neuroprotective effects. Resveratrol may activate cell specific signaling pathways that facilitate the activation of prosurvival mechanisms and enable the maintenance of mitochondrial integrity, thereby attenuating the multiple cell signaling pathways that cause cell death. Since multiple complex mechanisms mediate neurodegenerative processes, pharmacological agents like resveratrol, with broad spectrum biochemical properties, may hold promise for use as neuroprotective therapies. Pharmacological agents that target a specific mechanism often fail or are ineffective in clinical trials, possibly because of their narrow range of activity.
In summary, we demonstrate that resveratrol treatment is effective against the MA-induced apoptotic cell death process involving activation of caspase-3 and DNA fragmentation. Elucidation of the underlying mechanism of resveratrol neuroprotection in MA-induced apoptotic cell death may improve understanding of the molecular basis of this polyphenolic compound. Evaluation of the molecular mechanisms mediating the neuroprotective effects of resveratrol and other related polyphenols may lead to the development of novel therapies for the treatment of dopaminergic neurodegenerative processes associated with drugs of abuse as well as chronic neurodegenerative disorders including Parkinson’s disease.
ACKNOWLEDGEMENTS
This study was supported by National Institute of Health (NIH) grants NS38644, ES10586, and NS065167. The W. Eugene and Linda Lloyd Endowed Chair to AGK is also acknowledged.
REFERENCES
- 1.Seiden LS, Sabol KE. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res. Monogr. 1996;163:251–276. [PubMed] [Google Scholar]
- 2.Anglin MD, Burke C, Perrochet B, Stamper E, wud-Noursi S. History of the methamphetamine problem. J. Psychoact. Drugs. 2000;32:137–141. doi: 10.1080/02791072.2000.10400221. [DOI] [PubMed] [Google Scholar]
- 3.Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk G A, Shannak K, Haycock JW, Kish SJ. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996;2:699–703. doi: 10.1038/nm0696-699. [DOI] [PubMed] [Google Scholar]
- 4.Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology. 2000;54:1344–1349. doi: 10.1212/wnl.54.6.1344. [DOI] [PubMed] [Google Scholar]
- 5.Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 2001;21:9414–9418. doi: 10.1523/JNEUROSCI.21-23-09414.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am. J. Psychatry. 2003;160:1699–1701. doi: 10.1176/appi.ajp.160.9.1699. [DOI] [PubMed] [Google Scholar]
- 7.Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980;181:151–160. doi: 10.1016/0006-8993(80)91265-2. [DOI] [PubMed] [Google Scholar]
- 8.Gough B, Imam SZ, Blough B, Slikker W, Jr, Ali SF. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann. N. Y. Acad. Sci. 2002;965:410–420. doi: 10.1111/j.1749-6632.2002.tb04182.x. [DOI] [PubMed] [Google Scholar]
- 9.Fornai F, Lenzi P, Gesi M, Soldani P, Ferrucci M, Lazzeri G, Capobianco L, Battaglia G, De BA, Nicoletti F, Paparelli A. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 2004;88:114–123. doi: 10.1046/j.1471-4159.2003.02137.x. [DOI] [PubMed] [Google Scholar]
- 10.Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009;60:379–407. doi: 10.1016/j.brainresrev.2009.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry. 2001;158:377–382. doi: 10.1176/appi.ajp.158.3.377. [DOI] [PubMed] [Google Scholar]
- 12.Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002;24:308–318. doi: 10.1002/bies.10067. [DOI] [PubMed] [Google Scholar]
- 13.Jayanthi S, Ladenheim B, Cadet JL. Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann. N. Y. Acad. Sci. 1998;844:92–102. [PubMed] [Google Scholar]
- 14.LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 1999;19:1484–1491. doi: 10.1523/JNEUROSCI.19-04-01484.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Jeng W, Wong AW, Ting AK, Wells PG. Methamphetamine-enhanced embryonic oxidative DNA damage and neurodevelopmental deficits. Free Radic. Biol. Med. 2005;39:317–326. doi: 10.1016/j.freeradbiomed.2005.03.015. [DOI] [PubMed] [Google Scholar]
- 16.Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brain Res.Rev. 2001;36:1–22. doi: 10.1016/s0165-0173(01)00054-6. [DOI] [PubMed] [Google Scholar]
- 17.Wu CW, Ping YH, Yen JC, Chang CY, Wang SF, Yeh CL, Chi CW, Lee HC. Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis. Toxicol. Appl. Pharmacol. 2007;220:243–251. doi: 10.1016/j.taap.2007.01.011. [DOI] [PubMed] [Google Scholar]
- 18.Deng X, Cai NS, McCoy MT, Chen W, Trush MA, Cadet JL. Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology. 2002;42:837–845. doi: 10.1016/s0028-3908(02)00034-5. [DOI] [PubMed] [Google Scholar]
- 19.Jayanthi S, Deng X, Bordelon M, McCoy MT, Cadet J L. Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex. FASEB J. 2001;15:1745–1752. doi: 10.1096/fj.01-0025com. [DOI] [PubMed] [Google Scholar]
- 20.Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology. 1986;25:559–561. doi: 10.1016/0028-3908(86)90184-x. [DOI] [PubMed] [Google Scholar]
- 21.Wu PH, Shen YC, Wang YH, Chi CW, Yen JC. Baicalein attenuates methamphetamine-induced loss of dopamine transporter in mouse striatum. Toxicology. 2006;226:238–245. doi: 10.1016/j.tox.2006.06.015. [DOI] [PubMed] [Google Scholar]
- 22.Wang T, Arifoglu P, Ronai Z, Tew KD. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J. Biol. Chem. 2001;276:20999–21003. doi: 10.1074/jbc.M101355200. [DOI] [PubMed] [Google Scholar]
- 23.Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giuffrida S AM, Schapira T, Dinkova K AT, Rizzarelli E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem. Res. 2008;33:2444–2471. doi: 10.1007/s11064-008-9775-9. [DOI] [PubMed] [Google Scholar]
- 24.De Almeida LM, Leite MC, Thomazi AP, Battu C, Nardin P, Tortorelli LS, Zanotto C, Posser T, Wofchuk ST, Leal RB, Goncalves CA, Gottfried C. Resveratrol protects against oxidative injury induced by H2O2 in acute hippocampal slice preparations from Wistar rats. Arch. Biochem. Biophys. 2008;480:27–32. doi: 10.1016/j.abb.2008.09.006. [DOI] [PubMed] [Google Scholar]
- 25.Hwang JT, Kwon DY, Park OJ, Kim MS. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr. 2008;2:323–326. doi: 10.1007/s12263-007-0069-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Gelinas S, Martinoli MG. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J. Neurosci. Res. 2002;70:90–96. doi: 10.1002/jnr.10315. [DOI] [PubMed] [Google Scholar]
- 27.Gagne B, Gelinas S, Bureau G, Lagace B, Ramassamy C, Chiasson K, Valastro B, Martinoli MG. Effects of estradiol, phytoestrogens, and Ginkgo biloba extracts against 1-methyl-4-phenyl-pyridine-induced oxidative stress. Endocrine. 2003;21:89–95. doi: 10.1385/ENDO:21:1:89. [DOI] [PubMed] [Google Scholar]
- 28.Mercer LD, Kelly BL, Horne MK, Beart PM. Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochem. Pharmacol. 2005;69:339–345. doi: 10.1016/j.bcp.2004.09.018. [DOI] [PubMed] [Google Scholar]
- 29.Okawara M, Katsuki H E, Shibata H, Kume T, Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol. 2007;73:550–560. doi: 10.1016/j.bcp.2006.11.003. [DOI] [PubMed] [Google Scholar]
- 30.Bournival J, Quessy P, Martinoli MG. Protective effects of resveratrol and Quercetin against MPP(+) -induced oxidative stress act by modulating markers of apoptotic, death in dopaminergic neurons. Cell Mol. Neurobiol. 2009;29(8):1169–80. doi: 10.1007/s10571-009-9411-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kanthasamy A, Anantharam V, Ali SF, Kanthasamy AG. Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death. Ann. N. Y. Acad. Sci. 2006;1074:234–244. doi: 10.1196/annals.1369.022. [DOI] [PubMed] [Google Scholar]
- 32.Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, Kanthasamy AG. Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur. J. Neurosci. 2003;18:1387–1401. doi: 10.1046/j.1460-9568.2003.02864.x. [DOI] [PubMed] [Google Scholar]
- 33.Zhang D, Anantharam V, Kanthasamy A, Kanthasamy AG. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2007;322:913–922. doi: 10.1124/jpet.107.124669. [DOI] [PubMed] [Google Scholar]
- 34.Sun F, Kanthasamy A, Song C, Yang Y, Anantharam V, Kanthasamy AG. Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation. J. Cell Mol. Med. 2008;12:2467–2481. doi: 10.1111/j.1582-4934.2008.00293.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Afeseh NH, Kanthasamy A, Anantharam V, Song C, Witte T, Houk R, Kanthasamy AG. Vanadium induces dopaminergic neurotoxicity via protein kinase Cdelta dependent oxidative signaling mechanisms: relevance to etiopathogenesis of Parkinson's disease. Toxicol. Appl. Pharmacol. 2009;240:273–285. doi: 10.1016/j.taap.2009.07.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Deng X, Wang Y, Chou J, Cadet JL. Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method. Brain Res. Mol. Brain Res. 2001;93:64–69. doi: 10.1016/s0169-328x(01)00184-x. [DOI] [PubMed] [Google Scholar]
- 37.Jayanthi S, Deng X, Noailles PA, Ladenheim B, Cadet JL. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J. 2004;18:238–251. doi: 10.1096/fj.03-0295com. [DOI] [PubMed] [Google Scholar]
- 38.Zhu JP, Xu W, Angulo JA. Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience. 2006;140:607–622. doi: 10.1016/j.neuroscience.2006.02.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Jayanthi S, Ladenheim B, Cadet JL. Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann. N. Y. Acad. Sci. 1998;844:92–102. [PubMed] [Google Scholar]
- 40.Cubells JF, Rayport S, Rajendran G, Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 1994;14:2260–2271. doi: 10.1523/JNEUROSCI.14-04-02260.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Miyazaki I, Asanuma M, AZ-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, Ogawa N. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J. 2006;20:571–573. doi: 10.1096/fj.05-4996fje. [DOI] [PubMed] [Google Scholar]
- 42.Choi HJ, Yoo TM, Chung SY, Yang JS, Kim JI, Ha ES, Hwang O. Methamphetamine-induced apoptosis in a CNS-derived catecholaminergic cell line. Mol. Cells. 2002;13:221–227. [PubMed] [Google Scholar]
- 43.Kitazawa M, Wagner JR, Kirby ML, Anantharam V, Kanthasamy AG. Oxidative stress and mitochondrial-mediated apoptosis in dopaminergic cells exposed to methylcyclopentadienyl manganese tricarbonyl. J. Pharmacol. Exp. Ther. 2002;302:26–35. doi: 10.1124/jpet.302.1.26. [DOI] [PubMed] [Google Scholar]
- 44.Al Mutairy A, Al Kadasah S, Elfaki I, Arshaduddin M, Malik D, Al Moutaery K, Tariq M. Trolox ameliorates 3-nitropropionic acid-induced neurotoxicity in rats. Neurotoxicol. Teratol. 2010;32(2):226–33. doi: 10.1016/j.ntt.2009.09.003. [DOI] [PubMed] [Google Scholar]
- 45.Alvira D, Yeste-Velasco M, Folch J, Verdaguer E, Canudas AM, Pallas M, Camins A. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience. 2007;147:746–756. doi: 10.1016/j.neuroscience.2007.04.029. [DOI] [PubMed] [Google Scholar]
- 46.Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 2008;600:78–82. doi: 10.1016/j.ejphar.2008.10.005. [DOI] [PubMed] [Google Scholar]
- 47.Bournival J, Quessy P, Martinoli MG. Protective effects of resveratrol and Quercetin against MPP(+) -Induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol. Neurobiol. 2009;29:1169–80. doi: 10.1007/s10571-009-9411-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Blanchet J, Longpre F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32:1243–1250. doi: 10.1016/j.pnpbp.2008.03.024. [DOI] [PubMed] [Google Scholar]
- 49.Lee MK, Kang SJ, Poncz M, Song KJ, Park KS. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp. Mol. Med. 2007;39:376–384. doi: 10.1038/emm.2007.42. [DOI] [PubMed] [Google Scholar]
- 50.Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006;5:493–506. doi: 10.1038/nrd2060. [DOI] [PubMed] [Google Scholar]
- 51.Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–196. doi: 10.1038/nature01960. [DOI] [PubMed] [Google Scholar]
- 52.Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur. J. Pharmacol. 2008;591:66–72. doi: 10.1016/j.ejphar.2008.06.067. [DOI] [PubMed] [Google Scholar]
